KR20120091196A - 신규 아릴화 캄펜, 이들의 제조방법 및 이의 용도 - Google Patents

신규 아릴화 캄펜, 이들의 제조방법 및 이의 용도 Download PDF

Info

Publication number
KR20120091196A
KR20120091196A KR1020127011978A KR20127011978A KR20120091196A KR 20120091196 A KR20120091196 A KR 20120091196A KR 1020127011978 A KR1020127011978 A KR 1020127011978A KR 20127011978 A KR20127011978 A KR 20127011978A KR 20120091196 A KR20120091196 A KR 20120091196A
Authority
KR
South Korea
Prior art keywords
compound
disease
brain injury
branched
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127011978A
Other languages
English (en)
Korean (ko)
Inventor
라파엘 메초울람
리탈 마기드
에스테르 쇼아미
이타이 밥
Original Assignee
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120091196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. filed Critical 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디.
Publication of KR20120091196A publication Critical patent/KR20120091196A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
KR1020127011978A 2009-11-19 2010-11-18 신규 아릴화 캄펜, 이들의 제조방법 및 이의 용도 Ceased KR20120091196A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26267709P 2009-11-19 2009-11-19
US61/262,677 2009-11-19

Publications (1)

Publication Number Publication Date
KR20120091196A true KR20120091196A (ko) 2012-08-17

Family

ID=43875675

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127011978A Ceased KR20120091196A (ko) 2009-11-19 2010-11-18 신규 아릴화 캄펜, 이들의 제조방법 및 이의 용도

Country Status (25)

Country Link
US (2) US8722938B2 (enExample)
EP (1) EP2501669B1 (enExample)
JP (1) JP5960058B2 (enExample)
KR (1) KR20120091196A (enExample)
CN (1) CN102648174B (enExample)
AU (1) AU2010320467B2 (enExample)
BR (1) BR112012010518A2 (enExample)
CA (1) CA2774868C (enExample)
CL (1) CL2012001290A1 (enExample)
CO (1) CO6481008A2 (enExample)
CR (1) CR20120247A (enExample)
EC (1) ECSP12011864A (enExample)
ES (1) ES2665519T3 (enExample)
IL (1) IL218216A (enExample)
MA (1) MA33753B1 (enExample)
MX (2) MX355972B (enExample)
MY (1) MY184647A (enExample)
NZ (1) NZ599106A (enExample)
PE (1) PE20121187A1 (enExample)
PH (1) PH12012500897A1 (enExample)
RU (1) RU2578715C2 (enExample)
SG (2) SG10201407706VA (enExample)
UA (1) UA109414C2 (enExample)
WO (1) WO2011061744A2 (enExample)
ZA (1) ZA201200752B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190046017A (ko) * 2017-10-25 2019-05-07 대구대학교 산학협력단 캄펜을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2578715C2 (ru) * 2009-11-19 2016-03-27 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим, Лтд. Новые арилированные камфены, способы их получения и их применения
KR20170072876A (ko) 2014-10-27 2017-06-27 에프. 호프만-라 로슈 아게 방사성 표지된 카나비노이드 수용체 2 리간드
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
MX2018004632A (es) * 2015-10-16 2018-11-09 Scythian Biosciences Inc Metodos y composiciones para el tratamiento de una lesion cerebral traumatica.
EP3538507A1 (en) 2016-11-13 2019-09-18 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Process for the preparation of hu-910 and crystalline structure thereof
RU2651754C1 (ru) * 2016-11-25 2018-04-23 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) ПРИМЕНЕНИЕ АЛИФАТИЧЕСКИХ ИМИНОПРОИЗВОДНЫХ КАМФОРЫ В КАЧЕСТВЕ ЭФФЕКТИВНЫХ ИНГИБИТОРОВ РЕПРОДУКЦИИ ВИРУСА ГРИППА штамм A/California/07/09 (H1N1) pdm09 и A/Puerto Rico/8/34 (H1N1)
EP3840854A4 (en) * 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives
US20250002435A1 (en) * 2021-10-10 2025-01-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Arylated fenchone derivatives, compositions comprising them, processes for their preparation and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE876241C (de) * 1943-04-07 1953-05-11 Lech Chemie Gersthofen Verfahren zur Herstellung von Riechstoffen aus Terpenphenolen
US2537647A (en) * 1948-02-21 1951-01-09 Firestone Tire & Rubber Co Rearrangement of terpenyl aryl ethers
DE828394C (de) * 1948-10-02 1952-01-17 Chemische Werke Huels G M B H Verfahren zur Herstellung von UEberzuegen
US2647152A (en) * 1950-07-12 1953-07-28 Firestone Tire & Rubber Co Terpenylalkylphenols and their preparation
US3284359A (en) * 1963-12-26 1966-11-08 Gen Electric Barium potassium ferrite magnetic material exhibiting non-vanishing rotational hysteresis in applied magnetic fields
GB1306217A (enExample) * 1969-07-04 1973-02-07
US3800051A (en) * 1970-09-21 1974-03-26 Dow Chemical Co Reducing serum cholesterol with certain substituted phenols
US4112000A (en) * 1974-04-11 1978-09-05 Mar-Pha, Societe D'etude Et D'exploitation De Marques Terpenophenols
GB1504862A (en) * 1974-04-11 1978-03-22 Mar Pha Etu Expl Marques Terpeno-phenoxyalkylamines
GB1548875A (en) * 1975-06-23 1979-07-18 Mar Pha Etu Expl Marques Terpnyl phen (oxy)elkyl amideines and their use in pharmaceutical compositions
US5648352A (en) 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
HU227114B1 (en) 1999-05-11 2010-07-28 Egis Gyogyszergyar Nyilvanosan (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
ATE340158T1 (de) * 2000-11-08 2006-10-15 Syngenta Participations Ag Pyrrolcarboxamide und pyrrolcarbothioamide und deren agrochemische verwendungen
US8227643B2 (en) 2002-05-31 2012-07-24 Proteotech, Inc. Sirtuin 1 and the treatment of neurodegenerative diseases
US20070276034A1 (en) 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
US8455687B2 (en) 2002-05-31 2013-06-04 Proteotech, Inc. Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies
US7601876B2 (en) 2002-05-31 2009-10-13 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
PT1511710E (pt) * 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
RU2233262C1 (ru) * 2003-03-11 2004-07-27 Государственное учреждение Институт химии Коми научного центра Уральского отделения РАН Способ получения орто-терпенофенолов
CN1847207A (zh) * 2006-03-27 2006-10-18 上海应用技术学院 合成檀香的制备方法
RU2578715C2 (ru) * 2009-11-19 2016-03-27 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим, Лтд. Новые арилированные камфены, способы их получения и их применения

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190046017A (ko) * 2017-10-25 2019-05-07 대구대학교 산학협력단 캄펜을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CO6481008A2 (es) 2012-07-16
AU2010320467A1 (en) 2012-04-05
ECSP12011864A (es) 2012-07-31
PH12012500897A1 (en) 2012-11-12
SG10201407706VA (en) 2015-02-27
CN102648174A (zh) 2012-08-22
US20120245366A1 (en) 2012-09-27
CA2774868C (en) 2018-09-04
IL218216A (en) 2015-05-31
UA109414C2 (uk) 2015-08-25
SG179203A1 (en) 2012-04-27
MX355972B (es) 2018-05-07
EP2501669B1 (en) 2018-01-24
MX2012005634A (es) 2012-09-07
ES2665519T3 (es) 2018-04-26
RU2578715C2 (ru) 2016-03-27
US20150038728A1 (en) 2015-02-05
CL2012001290A1 (es) 2012-10-05
PE20121187A1 (es) 2012-09-23
CR20120247A (es) 2012-06-12
AU2010320467B2 (en) 2015-07-02
RU2012106897A (ru) 2013-12-27
JP5960058B2 (ja) 2016-08-02
JP2013511511A (ja) 2013-04-04
ZA201200752B (en) 2014-06-25
NZ599106A (en) 2013-07-26
MY184647A (en) 2021-04-13
EP2501669A2 (en) 2012-09-26
US8722938B2 (en) 2014-05-13
WO2011061744A2 (en) 2011-05-26
MA33753B1 (fr) 2012-11-01
IL218216A0 (en) 2012-04-30
CN102648174B (zh) 2016-04-27
BR112012010518A2 (pt) 2016-03-15
US9365534B2 (en) 2016-06-14
CA2774868A1 (en) 2011-05-26
WO2011061744A3 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
US9365534B2 (en) Arylated camphenes, processes for their preparation and uses thereof
JP5059996B2 (ja) 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法
US20040087590A1 (en) Novel biphenyl and biphenyl-like cannabinoids
US6563009B1 (en) Vasodilator cannabinoid analogs
Ladopoulou et al. Antihyperlipidemic morpholine derivatives with antioxidant activity: An investigation of the aromatic substitution
CN101434517A (zh) 治疗免疫疾病的新的1,2-二苯基乙烯衍生物
CA3110208A1 (en) Applications of known and novel cannabinoids
WO2004073612A2 (en) Estrogen receptor modulators
US20050020544A1 (en) Bicyclic CB2 cannabinoid receptor ligands
JP2007536238A (ja) エストロゲン受容体で活性を持つ化合物
TW200306814A (en) Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X(RXR)receptors
JP6234990B2 (ja) 動脈硬化性血管疾患を処置するための方法及び組成物
IL237753A (en) Aryl-backed campaigns, processes for their preparation and use
Lambooy The Synthesis of 6, 7-Diethyl-9-(D-11-ribityl)-isoalloxazine1
AU2016273882B2 (en) Opsin-binding ligands, compositions and methods of use
HK1169095A (en) Novel arylated camphenes, processes for their preparation and uses thereof
KR100257183B1 (ko) 측백엽으로부터 피누솔라이드를 추출하는 방법 및 이를 주성분으로 함유하는 paf-길항제
KR20170097422A (ko) 피스아타놀 유도체 합성방법 및 피스아타놀 유도체를 포함하는 항염증 약학 조성물
JP2007262022A (ja) 新規２−チオフェンカルボキサミド誘導体
CN107304199A (zh) 一种新的喜巴辛类似物及其在医药中的应用
JP2005035895A (ja) 高カルシウム血症および骨疾患治療剤
TW201930309A (zh) Ask1抑制劑化合物及其用途
HK1206329B (en) Phenol derivative, method of preparing same, and pharmaceutical application of same
HK1084657B (en) Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151118

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20151118

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151210

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160628

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151210

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I